Life Science Investing Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer's Disease Trial 09 September
Life Science Investing Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025 02 September
Life Science Investing Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine 26 August
